

GLOBAL CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET FORECAST 2018-2026

https://marketpublishers.com/r/GE17C8491ADEN.html

Date: May 2018

Pages: 120

Price: US\$ 2,500.00 (Single User License)

ID: GE17C8491ADEN

Abstracts

KEY FINDINGS

Global Chronic Idiopathic Constipation drug market is estimated to grow at a CAGR of 8.42% during the forecast period of 2018-2026. The important drivers propelling the market growth are the modern dietary habits, rising elderly population and the improved and efficient drugs in the pipeline. Linaclotide is a major type of drug that is popular in this market.

MARKET INSIGHT

The CIC drug market is segmented based on drug types and also on the basis of prescription types. The drug types include Linaclotide, Lubiprostone, and others. The prescription type segment is further divided into over the counter drugs and prescribed drugs. An increasing demand for CIC drug from the Asia-Pacific market, coupled with the high unmet needs globally is providing the market with plenty of growth opportunities.

REGIONAL INSIGHTS

Geographically, the global CIC drug market is segmented four major regions which include North America, Asia Pacific, Europe and Rest of World. North America is touted to account for the largest share during the forecast period on account of its developed healthcare systems and medical devices industry. Approximately xx% of the population residing there suffer from CIC. The growing government initiatives to treat and improve the healthcare segment of the society by providing latest technological and advance medical treatments are also aiding the market growth.

COMPETITIVE INSIGHTS



Advanced product launch is the key strategy adopted by the various market players of global CIC drug market. The other strategies include acquisition and mergers. For example, Roche holding Inc acquired Ariosa Diagnostics Inc, which provides non-invasive prenatal testing (NIPT) service using cell-free DNA (cf-DNA) technology. Also, Allergan announced a collaboration with the company AstraZeneca in order to develop and commercialize ATM-AVI (aztreonam and avibactam) for antibiotic-resistant gramnegative infections. The other major players in the market include Synergy Pharmaceuticals, GlaxoSmithKline, Sucampo Pharmaceuticals Inc, Pfizer, Ironwood Pharmaceuticals Inc, etc.



Contents

1. RESEARCH SCOPE

- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

- 2.1. SOURCES OF DATA
 - 2.1.1. SECONDARY DATA
 - 2.1.2. PRIMARY DATA
- 2.2. TOP DOWN APPROACH
- 2.3. BOTTOM-UP APPROACH
- 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

3.1. MARKET SUMMARY

4. MARKET OVERVIEW

- 4.1. MARKET DEFINITION
- 4.2. KEY MARKET INSIGHTS
- 4.3. ATTRACTIVE INVESTMENT SCENARIO
- 4.4. POSITION OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
- 4.5. MARKET DRIVERS
 - 4.5.1. MODERN DIETARY HABITS TAKING A TOLL ON THE HEALTH
 - 4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
 - 4.5.3. INCREASING ELDERLY POPULATION
 - 4.5.4. IMPROVED AND EFFICIENT DRUGS IN THE PIPELINE
- 4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
- 4.6. RESTRAINTS
 - 4.6.1. SURGICAL TREATMENTS
- 4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
- 4.7. OPPORTUNITIES



- 4.7.1. INCREASING DEMAND FOR CIC DRUG FROM APAC MARKET
- 4.7.2. HIGH UNMET NEEDS
- 4.8. CHALLENGES
 - 4.8.1. SIDE EFFECTS OF CIC DRUGS

5. GLOBAL CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 (\$ MILLION)

- 5.1. OVERVIEW
 - 5.1.1. LUBIPROSTONE
 - 5.1.2. LINACLOTIDE
 - 5.1.3. OTHERS
- 5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, \$ MILLION)
- 5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, \$ MILLION)

6. GLOBAL CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

- 6.1. PRESCRIBED DRUGS
- 6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS

- 7.1. PORTER'S FIVE FORCE ANALYSIS
 - 7.1.1. INTENSITY OF COMPETITIVE RIVALRY
 - 7.1.2. BARGAINING POWER OF SUPPLIERS
 - 7.1.3. BARGAINING POWER OF BUYERS
 - 7.1.4. THREAT OF SUBSTITUTE PRODUCTS
 - 7.1.5. THREAT OF NEW ENTRANTS
- 7.2. VENDOR LANDSCAPE
- 7.3. OPPORTUNITY MATRIX

8. GLOBAL CIC DRUGS MARKET BY GEOGRAPHY 2018-2026 (\$ MILLION)

- 8.1. NORTH AMERICA
 - 8.1.1. US
 - 8.1.2. CANADA
- 8.2. EUROPE



- 8.2.1. UK
- **8.2.2. GERMANY**
- 8.2.3. REST OF EUROPE
- 8.3. ASIA PACIFIC
 - 8.3.1. CHINA
 - 8.3.2. JAPAN
 - 8.3.3. REST OF ASIA PACIFIC
- 8.4. REST OF THE WORLD
 - 8.4.1. MIDDLE EAST AND AFRICA
 - 8.4.2. LATIN AMERICA

9. COMPANY PROFILES

- 9.1. ALLERGENS
 - 9.1.1. OVERVIEW
 - 9.1.2. PRODUCT PORTFOLIO
 - 9.1.3. STRATEGIC MOVES
 - 9.1.4. SCOT ANALYSIS
- 9.2. CHUGAI PHARMACEUTICAL
 - 9.2.1. OVERVIEW
 - 9.2.2. PRODUCTS PORTFOLIO
 - 9.2.3. STRATEGIC MOVES
 - 9.2.4. SCOT ANALYSIS
- 9.3. FERRING INTERNATIONAL CENTER S.A.
 - 9.3.1. OVERVIEW
 - 9.3.2. PRODUCTS PORTFOLIO
 - 9.3.3. SCOT ANALYSIS
- 9.4. SYNERGY PHARMACEUTICALS
 - 9.4.1. OVERVIEW
 - 9.4.2. PRODUCTS PORTFOLIO
 - 9.4.3. SCOT ANALYSIS
- 9.5. PFIZER
 - 9.5.1. OVERVIEW
 - 9.5.2. PFIZER PRODUCT PORTFOLIO
 - 9.5.3. SCOT ANALYSIS
- 9.6. GLAXOSMITHKLINE
 - 9.6.1. OVERVIEW
 - 9.6.2. PRODUCT PORTFOLIO
 - 9.6.3. SCOT ANALYSIS



- 9.7. ROCHE HOLDING AG
 - 9.7.1. OVERVIEW
 - 9.7.2. PRODUCT PORTFOLIO
 - 9.7.3. STRATEGIC MOVES
 - 9.7.4. SCOT ANALYSIS
- 9.8. SANOFI
 - 9.8.1. OVERVIEW
 - 9.8.2. PRODUCTS PORTFOLIO
 - 9.8.3. SCOT ANALYSIS
- 9.9. BAYER AG
 - 9.9.1. OVERVIEW
 - 9.9.2. PRODUCTS PORTFOLIO
 - 9.9.3. SCOT ANALYSIS
- 9.10. MERCK SHARP & DOHME
 - 9.10.1. OVERVIEW
 - 9.10.2. PRODUCT PORTFOLIO
 - 9.10.3. SCOT ANALYSIS
- 9.11. ELI LILLY AND COMPANY
 - 9.11.1. OVERVIEW
 - 9.11.2. PRODUCT PORTFOLIO
 - 9.11.3. SCOT ANALYSIS
- 9.12. SALIX PHARMACEUTICALS LTD
 - 9.12.1. OVERVIEW
 - 9.12.2. PRODUCT PORTFOLIO
 - 9.12.3. SCOT ANALYSIS
- 9.13. SUCAMPO PHARMACEUTICALS INC
 - 9.13.1. OVERVIEW
 - 9.13.2. PRODUCT PORTFOLIO
 - 9.13.3. SCOT ANALYSIS
- 9.14. IRONWOOD PHARMACEUTICALS INC
 - 9.14.1. OVERVIEW
 - 9.14.2. PRODUCT PORTFOLIO
 - 9.14.3. SCOT ANALYSIS
- 9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
 - 9.15.1. OVERVIEW
- 9.16. DAIICHI SANKYO CO LTD
 - 9.16.1. OVERVIEW
 - 9.16.2. PRODUCT PORTFOLIO
 - 9.16.3. SCOT ANALYSIS



- 9.17. COSMO PHARMACEUTICALS SA
 - 9.17.1. OVERVIEW
 - 9.17.2. PRODUCT PORTFOLIO
 - 9.17.3. SCOT ANALYSIS
- 9.18. PROGENICS PHARMACEUTICALS INC
 - 9.18.1. OVERVIEW
 - 9.18.2. PRODUCT PORTFOLIO
 - 9.18.3. SCOT ANALYSIS
- 9.19. THERAVANCE BIOPHARMA INC
 - 9.19.1. OVERVIEW
 - 9.19.2. PRODUCT PORTFOLIO
 - 9.19.3. SCOT ANALYSIS



List Of Tables

LIST OF TABLES

TABLE 1 GLOBAL CIC DRUG MARKET BY GEOGRAPHY 2018-2026 (\$ MILLION)

TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN

THERAPEUTICS FOR CHRONIC CONSTIPATION

TABLE 3 CONSTIPATION IN PARKINSON'S DISEASE

TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION

TABLE 5 GLOBAL CIC DRUGS MARKET BY DRUG TYPE 2018-2026 (\$ MILLION)

TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 7 LUBIPROSTONE DRUG MARKET BY GEOGRAPHY 2018-2026 (\$ MILLION)

TABLE 8 PRODUCT PROFILE (LINACLOTIDE)

TABLE 9 LINACLOTIDE DRUG MARKET BY GEOGRAPHY 2018-2026 (\$ MILLION)

TABLE 10 PRODUCT PROFILE (BISACODYL)

TABLE 11 OTHERS DRUG MARKET BY GEOGRAPHY 2018-2026 (\$ MILLION)

TABLE 12 PIPELINE PRODUCT PROFILE (PLECANATIDE)

TABLE 13 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)

TABLE 14 GLOBAL CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 15 GLOBAL PRESCRIBED CIC DRUGS MARKET, BY GEOGRAPHY 2018-2026 (\$ MILLION)

TABLE 16 LINZESS PRECAUTIONS AND SIDE EFFECTS

TABLE 17 GLOBAL OVER THE COUNTER CIC DRUG MARKET BY GEOGRAPHY 2018-2026 (\$ MILLION)

TABLE 18 NORTH AMERICA CIC DRUGS MARKET BY COUNTRY 2018–2026 (\$ MILLION)

TABLE 19 U.S. CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 20 U.S. CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION)

TABLE 21 CANADA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 22 CANADA CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION)

TABLE 23 EUROPE CIC DRUGS MARKET BY COUNTRY 2018-2026 (\$ MILLION)

TABLE 24 UK CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 25 UK CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION)

TABLE 26 GERMANY CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$



MILLION)

TABLE 27 GERMANY CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION)

TABLE 28 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2018-2026 (\$ MILLION)

TABLE 29 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 30 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION) TABLE 31 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 32 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION) TABLE 33 REST OF WORLD CIC DRUGS MARKET, BY REGION, 2018-2026 (\$ MILLION)

TABLE 34 MENA CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 35 MENA CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION) TABLE 36 LATIN AMERICA CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 37 LATIN AMERICA CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION)



List Of Figures

LIST OF FIGURES

FIGURE 1 GLOBAL CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 2 GLOBAL CIC DRUG MARKET BY DRUG TYPE 2018-2026 (\$ MILLION)

FIGURE 3 GLOBAL CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 (%)

FIGURE 4 CAUSES OF CONSTIPATION

FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014

FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE

FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS

FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION

FIGURE 9 NEED OF SURGERY PROCESS

FIGURE 10 APAC CIC MARKET 2018-2026 (\$ MILLION)

FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM

FIGURE 12 GLOBAL LUBIPROSTONE DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 13 GLOBAL LINACLOTIDE DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 14 GLOBAL OTHER DRUGS MARKET 2018-2026 (\$ MILLION)

FIGURE 15 GLOBAL PRESCRIBED CIC DRUGS MARKET 2018-2026 (\$ MILLION)

FIGURE 16 GLOBAL OVER THE COUNTER CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 17 NORTH AMERICA CIC DRUGS MARKET 2018–2026 (\$ MILLION)

FIGURE 18 US CIC MARKET, 2018-2026 (\$ MILLION)

FIGURE 19 CANADA CIC MARKET 2018-2026 (\$ MILLION)

FIGURE 20 EUROPE CIC DRUGS MARKET 2018-2026 (\$ MILLION)

FIGURE 21 UK CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 22 GERMANY CIC DRUG MARKET, 2018-2026 \$ MILLION)

FIGURE 23 REST OF EUROPE CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 24 ASIA PACIFIC CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 25 CHINA CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 26 COMPARISON OF PHARMACEUTICAL SALES ACROSS THE GLOBE

FIGURE 27 JAPAN CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 28 REST OF APAC CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 29 MIDDLE EAST & AFRICA CIC DRUGS MARKET 2018-2026 (\$ MILLION)

FIGURE 30 LATIN AMERICA CIC DRUG MARKET 2018-2026 (\$ MILLION)

COMPANIES MENTIONED



- 1. ALLERGENS
- 2. CHUGAI PHARMACEUTICAL
- 3. FERRING INTERNATIONAL CENTER S.A.
- 4. SYNERGY PHARMACEUTICALS
- 5. PFIZER
- 6. GLAXOSMITHKLINE
- 7. ROCHE HOLDING AG
- 8. SANOFI
- 9. BAYER AG
- 10. MERCK SHARP & DOHME
- 11. ELI LILLY AND COMPANY
- 12. SALIX PHARMACEUTICALS LTD
- 13. SUCAMPO PHARMACEUTICALS INC
- 14. IRONWOOD PHARMACEUTICALS INC
- 15. VALEANT PHARMACEUTICALS INTERNATIONAL
- 16. DAIICHI SANKYO CO LTD
- 17. COSMO PHARMACEUTICALS SA
- 18. PROGENICS PHARMACEUTICALS INC
- 19. THERAVANCE BIOPHARMA INC



I would like to order

Product name: GLOBAL CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET FORECAST

2018-2026

Product link: https://marketpublishers.com/r/GE17C8491ADEN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE17C8491ADEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



